OnePin Peptide Library · Metabolic
Semaglutide
Ozempic · Wegovy · Rybelsus
Semaglutide is a GLP-1 receptor agonist FDA-approved as Ozempic (diabetes), Wegovy (obesity), and Rybelsus (oral diabetes). It reduces appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. Weekly injectable formulation provides sustained GLP-1 activation. Semaglutide produced approximately 15-17% body weight loss in clinical trials, revolutionizing obesity treatment. It is a single-agonist (GLP-1 only) compared to tirzepatide (dual GLP-1/GIP) and retatrutide (triple GLP-1/GIP/glucagon).
SubQ: Any time, any day, with or without food. Once weekly on the same day. Oral (Rybelsus): Must be taken on empty stomach with no more than 4oz water, 30 minutes before food/drink/other meds.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Semaglutide binds GLP-1 receptors in the pancreas (enhancing glucose-dependent insulin secretion), hypothalamus (suppressing appetite), and GI tract (slowing gastric emptying). Albumin binding extends half-life to approximately 7 days enabling weekly dosing. Unlike natural GLP-1 (2-minute half-life), semaglutide provides sustained receptor activation.
Semaglutide binds GLP-1 receptors in the pancreas (enhancing glucose-dependent insulin secretion), hypothalamus (suppressing appetite), and GI tract (slowing gastric emptying). Albumin binding extends half-life to approximately 7 days enabling weekly dosing. Unlike natural GLP-1 (2-minute half-life), semaglutide provides sustained receptor activation.
What to expect
Weeks 1-4: Appetite suppression begins during titration. Nausea common.
Weeks 4-12: Consistent weight loss. GI side effects improve.
Months 3-12: Significant cumulative weight loss. Metabolic improvements.
Evidence
The honest take
Cardiovascular benefit
SELECT trial showed 20% reduction in major cardiovascular events. First GLP-1 with dedicated CV outcome data in obesity.
Confirmed across STEP trial program. FDA-approved for chronic weight management.
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Safe & synergistic
Keep separate
Side effects & safety
Commonly reported
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
- Vomiting during titration
Less common & notes
- Pancreatitis risk (class effect).
- Gallbladder issues.
- Gastroparesis.
- Thyroid C-cell tumor signal in rodents.
- Contraindicated with MTC/MEN2 history.
- Oral contraceptives may be less reliable during dose initiation and escalation: delayed gastric emptying (GLP-1 / amylin) can reduce oral drug absorption - Tirzepatide carries an FDA label warning to use a backup or non-oral method for 4 weeks after starting and after each dose increase.
Pharmacokinetics
Storage. Pre-filled pens: 56 days room temp. Compounded: 28 days 2-8C.
Regulatory status
FDA-approved as Ozempic, Wegovy, Rybelsus. WADA prohibited under S4 in competition. Schedule varies by country.
Put it to work
Calculate, log & track
Open Semaglutide straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Semaglutide in the app →Go deeper
The guide & community
The complete Semaglutide walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗